Abstract
In addition to estrogen widely used all over the world for the prevention of postmenopausal osteoporosis, calcitonin and vitamin D derivatives are commonly employed to treat established osteoporosis at higher age in Japan. In order to critically assess the usefulness of vitamin D derivatives and calcitonin alone or in combination on the advancement of vertebral deformity at higher age, 32 osteoporotic patients with vertebral deformity with the mean age of 79 were randomly divided into 4 groups with indistinguishable age and severity of the vertebral deformity. Group 1 served as the control without specific medications for osteoporosis. Group 2 was treated with 10 units elcatonin (eel calcitonin derivative) injected intramuscularly twice a week. Group 3 was given 0.75 to 1.5µg/day 1α (OH) vitamin D3 orally. Group 4 was given a combination of treatments used in Groups 2 and 3.
In the lateral X-ray film of the spine taken prior to the test and every 6 months thereafter, the shape of the vertebral body T8 through L4 was monitored by measuring the anterior, central and posterior heights. Decrease of the vertebral height ratio; anterior or middle height/posterior or adjacent intact posterior height, by more than 20% of the original value or from above to below 0.80 both appeared to be inhibited during administration of 1α (OH) vitamin D3. Such effect seems to be augmented by simultaneous administration of elcatonin. Actual decrease of vertebral height ratio values and the per cent fall from the original value significantly less in Groups 3 and 4 than in Group 1. Development of vertebral deformity assessed by the changes of the vertebral height thus appears to decrease during treatment with 1α (OH) vitamin D3 especially together with calcitonin in established osteoporosis.
Similar content being viewed by others
References
Hillner, B., Hollenberg, J.P., Pauker, S.G.: Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Amer. J. Med. 80: 1115–1127, 1986
Davis, M.E., Strandjord, N.M., Lanzl, L.H.: Estrogens and the aging process. The detection, prevention and retardation of osteoporosis. J. Amer. Med. Ass. 196: 129–134, 1966
Fatourechi, V., Heath, H. III: Salmon calcitonin in the treatment of postmenopausal osteoporosis. Ann. Intern. Med. 107: 923–925, 1987
Fujita, T.: Studies of osteoporosis in Japan. Metabolism 39:Suppl. 39–42, 1990
Shimizu, S.: Osteoporosis among patients with hip fracture in Japan. J. Bone and Miner. Metab. (in press)
Riggs, B.L., Seeman, E., Hodgson, S.F., Taves, D.R., O'Fallon, M.: Effect of the fluoride calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. New Engl. J Med. 306: 446–450, 1982
Gallagher, J.C., Jerpbak, C.M., Jee, W.S.S., Johnston, K.A., DeLuca, H.F., Riggs, B.L.: Administration of 1,25-dihydroxyvitamin D3 to patients with postmenopausal osteoporosis: short and long term effects on bone and calcium metabolism. Proc. Nat. Acad. Sci. 79: 3325–3329, 1982
Gallagher, J.C., Riggs, B.L., Recker, R.R., Goldgar, D.: The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc. Soc. Exp. Biol. and Med. 191: 287–292, 1989
Itami, Y., Fujita, T., Inoue, T. et al: Effect of alphacalcidol (1α (OH) D3) on osteoporosis. A multicenter double-blind study. J. Clon. Exp. Med. (Tokyo) 123: 958–973, 1982
Orimo, H., Shiraki, M., Hayashi, T., Nakamura, T.: Reduced occurrence of vertebral crush fracture in senile osteoporosis treated with 1α (OH) vitamin D3. Bone Miner. 3: 41–52, 1987
Shiraki, M., Orimo, H., Ito, H., Akiguchi, I., Nakao, J., Takahashi, R. Ishizuka, S.: Long term treatment of postmenopausal osteoporosis with active vitamin D3, 1α-hydroxycholecalciferol (1α-OHD3) and 1,24-dihydroxycholecalciferol (1,24 (OH)2 D3). Endocrinol. Japon. 32: 305–315, 1985
Gallagher, J.H., Goldgar, D.: Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized clinical study. Ann. Intern, Med. 113: 649–655, 1990
Christiansen, C., Christiansen, M.S., Rodbro, P., Hagen, C., Transbol, I.: Effect of 1,25-dihydroxyvitamin D3 in itself or combined with hormone treatment in preventing osteoporosis. Europ. J. Clin. Invest. II: 305–309, 1981
Author information
Authors and Affiliations
About this article
Cite this article
Fujita, T., Fukase, M., Shimada, T. et al. Treatment of established osteoporosis with 1α (OH) vitamin D3 and low dose intermittent elcatonin (eel calcitonin derivative). J Bone Miner Metab 10, 37–40 (1992). https://doi.org/10.1007/BF02383460
Issue Date:
DOI: https://doi.org/10.1007/BF02383460